Myeloproliferative Neoplasms and Cardiovascular Disease: A Review

Area of Science:

• Hematology
• Cardiology
• Oncology

Background:

• Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders driven by JAK/STAT pathway activation.
• Cardiovascular disease (CVD) is a major cause of morbidity and mortality in MPN patients.
• MPNs are associated with both thrombotic and non-thrombotic cardiovascular complications.

Purpose of the Study:

• To review the spectrum of cardiovascular complications in MPN.
• To highlight the need for improved CVD prevention strategies in MPN.
• To raise clinician awareness of MPN-associated cardiovascular risks.

Main Methods:

• Literature review of recent studies on MPN and CVD outcomes.
• Analysis of cardiovascular complications including acute myocardial infarction, heart failure, atrial fibrillation, and pulmonary hypertension.
• Discussion of current understanding and gaps in CVD prevention for MPN patients.

Main Results:

• MPN patients face significant risks for various CVDs, including thrombotic events, heart failure, arrhythmias, and pulmonary hypertension.
• Specific outcomes for acute myocardial infarction, heart failure, atrial fibrillation, and pulmonary hypertension in MPN patients have been characterized.
• Optimal strategies for cardiovascular disease prevention in MPN are not yet established.

Conclusions:

• Clinicians must recognize the broad range of cardiovascular complications in MPN, encompassing thrombotic and non-thrombotic conditions.
• Further research is essential to enhance cardiovascular outcomes for individuals with MPN.
• Awareness and proactive management of CVD are crucial for improving the prognosis of MPN patients.